[EN] PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB<br/>[FR] PROCÉDÉ ET INTERMÉDIAIRES POUR LA PRÉPARATION D'UPADACITINIB
申请人:CRYSTAL PHARMA SAU
公开号:WO2021123288A1
公开(公告)日:2021-06-24
The invention relates to a process for the preparation of compounds of formula (I), which are useful intermediates in the synthesis of Upadacitinib and structurally related compounds, by using Weinreb amide (III), or an equivalent thereof, as key intermediate.
[EN] PREPARATION METHODS FOR UPADACITINIB AND INTERMEDIATE THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION DE L'UPADACITINIB ET D'UN INTERMÉDIAIRE DE CELUI-CI<br/>[ZH] 乌帕替尼及其中间体的制备方法
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpla]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
申请人:AbbVie Inc.
公开号:US20180141955A1
公开(公告)日:2018-05-24
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.